Biomarin Pharmaceutical (BMRN) Net Margin (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Net Margin data on file, last reported at 13.77% in Q1 2026.

• Quarterly Net Margin fell 1115.0% year-over-year to 13.77% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8.29% (down 947.0% YoY) and the FY2025 annual result came in at 10.83%, down 413.0% from the prior year.
• Net Margin advanced to 13.77% in Q1 2026, from 5.33% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 29.14% in Q2 2025 to a low of 5.33% in Q4 2025.
• A 5-year average of 10.2% and a median of 9.41% in 2023 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2022 — Net Margin soared 1968 bps — and 2025, when it tumbled 2204 bps.
• Tracing BMRN's Net Margin over 5 years: stood at 0.05% in 2022, then soared by 6907 bps to 3.15% in 2023, then soared by 430 bps to 16.72% in 2024, then slumped by 132 bps to 5.33% in 2025, then soared by 359 bps to 13.77% in 2026.
• The last three Net Margin figures came in at 13.77% (Q1 2026), 5.33% (Q4 2025), and 3.96% (Q3 2025), per Business Quant data.